While numerous cellular signaling pathways contribute to ischemic stroke pathology, this review concentrates on the RhoA kinase pathway and mTOR (mammalian target of rapamycin) as promising therapeutic targets, as well as secretome-based treatments, which have the potential to modulate multiple aspects of stroke pathology and potentially complement existing therapeutic approaches. The gene discussed is MTOR; the disease is ischemic stroke.